EMMPIRRIN (CD147) and matrix metalloproteinase-9 (MMP9) immunohistochemical expression in breast carcinoma: Relationship with clinicopathological paremeters | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Article 6, Volume 4, Issue 1 - Serial Number 5, April 2020, Page 35-42 PDF (3.14 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2020.26206.1015 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shorouk Mowafy; Basma Amer 
| ||||
| Pathology Department, Faculty of Medicine Tanta University, Tanta, Egypt | ||||
| Abstract | ||||
| Background: Breast cancer is one of the leading causes of cancer mortality in women worldwide. Despite significant advances in cancer treatment, mortality results from local invasion and/or distant metastasis. Aim: To evaluate EMMPIRIN (CD147) and matrix metalloproteinase-9 (MMP9) immunohistochemical expressions significance in invasive ductal breast carcinoma cases in relation to other clinicopathological parameters. Materials and Methods: The study included 50 specimens of surgically resected breast carcinomas in which the expression of CD147and MMP9 was assessed. The results were compared statistically with chi-square (χ2) and Fisher exact test. Results: CD174 overexpression showed significant association with poorly differentiated tumors, staging, presence of nodal metastasis and high Ki67 expression. There was a significant correlation between high MMP9 expression and pathological variables as tumor staging, positive nodal metastasis, low ER expression and high HER2 expression. Conclusion: The results of this study suggest that high expressions of EMMPRIN and MMP9 correlate to poor prognostic parameters. Targeted therapy might improve the prognosis of patients with CD147 and MMP-9 overexpression. | ||||
| Keywords | ||||
| Keywords: EMMPIRIN; Matrix metalloproteinase 9; Breast carcinoma; Immunohistochemistry (IHC) | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 295 PDF Download: 288 |
||||
